{"filing":{"accession_number":"0001213900-26-110497","cik":"0001795091","ticker":"OSTX","company_name":"OS Therapies Inc","form":"8-K","filing_date":"2026-10-19","report_date":"2026-10-15","primary_document":"ea0308599-8k_ostherapies.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1795091/000121390026110497/ea0308599-8k_ostherapies.htm"},"events":[{"id":35983,"run_id":33172,"accession_number":"0001213900-26-110497","anchor_item_number":"3.02","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"OS Therapies completed the initial closing of a warrant exercise inducement and exchange offer on October 15, 2026, generating $7.2 million in gross proceeds from accredited investors. The Company issued 5,517,253 new common stock purchase warrants at $1.40 per share in exchange for the exercise or pre-funding of existing warrants at a reduced exercise price of $1.30 per share, with potential total proceeds of $12.3 million if all existing warrants are exercised. The securities were offered in reliance on Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D and have not been registered under the Securities Act.","company_name":"OS Therapies Inc","ticker":"OSTX","filing_date":"2026-10-19","form":"8-K","submitted_at":null,"items":[{"id":40241,"accession_number":"0001213900-26-110497","item_number":"1.01","item_title":"Entry into a Material Definitive","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"OS Therapies conducted a warrant exercise inducement and exchange offer to accredited investors, resulting in the issuance of new warrants and common stock. The Initial Closing on October 15, 2026 generated $7.2 million in gross proceeds and resulted in the issuance of 5,517,253 new warrants, with potential total proceeds of $12.3 million if all existing warrants are exercised. This is a private placement of equity securities to a limited group of accredited investors designed to raise capital, characteristic of a dilutive issuance. While structured as a warrant exchange, the economic substance is the issuance of new equity securities (warrants) in exchange for cash proceeds.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-19T12:48:48.397842+00:00","company_name":"","ticker":null,"filing_date":""},{"id":40242,"accession_number":"0001213900-26-110497","item_number":"3.02","item_title":"Unregistered Sales of Equity Securities.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"OS Therapies conducted a warrant exercise inducement and exchange offer resulting in $7.2 million in gross proceeds from the exercise or pre-funding of 5,517,253 common stock purchase warrants at a reduced exercise price of $1.30 per share, with new warrants issued in consideration. The securities were offered in reliance on Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D—classic private placement exemptions—and have not been registered under the Securities Act. This is a material dilutive equity issuance typical of small-cap biotech companies raising capital.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-19T12:48:48.397842+00:00","company_name":"","ticker":null,"filing_date":""},{"id":40243,"accession_number":"0001213900-26-110497","item_number":"8.01","item_title":"Other Events.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"OS Therapies announced the initial closing of a warrant exercise inducement and exchange offer that generated $7.2 million in gross proceeds through the exercise or pre-funding of existing warrants by accredited investors. The Company issued new common stock purchase warrants to purchase 5,517,253 shares at $1.40 per share in consideration for the warrant exercises. This is a private placement of equity securities (warrants and underlying shares) to a limited group of accredited investors, structured as a dilutive capital raise to fund operating runway and regulatory submissions for Herlystic™.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-19T12:48:48.397842+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":40241,"accession_number":"0001213900-26-110497","item_number":"1.01","item_title":"Entry into a Material Definitive","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"OS Therapies conducted a warrant exercise inducement and exchange offer to accredited investors, resulting in the issuance of new warrants and common stock. The Initial Closing on October 15, 2026 generated $7.2 million in gross proceeds and resulted in the issuance of 5,517,253 new warrants, with potential total proceeds of $12.3 million if all existing warrants are exercised. This is a private placement of equity securities to a limited group of accredited investors designed to raise capital, characteristic of a dilutive issuance. While structured as a warrant exchange, the economic substance is the issuance of new equity securities (warrants) in exchange for cash proceeds.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-19T12:48:48.397842+00:00","company_name":"OS Therapies Inc","ticker":"OSTX","filing_date":"2026-10-19"},{"id":40242,"accession_number":"0001213900-26-110497","item_number":"3.02","item_title":"Unregistered Sales of Equity Securities.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"OS Therapies conducted a warrant exercise inducement and exchange offer resulting in $7.2 million in gross proceeds from the exercise or pre-funding of 5,517,253 common stock purchase warrants at a reduced exercise price of $1.30 per share, with new warrants issued in consideration. The securities were offered in reliance on Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D—classic private placement exemptions—and have not been registered under the Securities Act. This is a material dilutive equity issuance typical of small-cap biotech companies raising capital.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-19T12:48:48.397842+00:00","company_name":"OS Therapies Inc","ticker":"OSTX","filing_date":"2026-10-19"},{"id":40243,"accession_number":"0001213900-26-110497","item_number":"8.01","item_title":"Other Events.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"OS Therapies announced the initial closing of a warrant exercise inducement and exchange offer that generated $7.2 million in gross proceeds through the exercise or pre-funding of existing warrants by accredited investors. The Company issued new common stock purchase warrants to purchase 5,517,253 shares at $1.40 per share in consideration for the warrant exercises. This is a private placement of equity securities (warrants and underlying shares) to a limited group of accredited investors, structured as a dilutive capital raise to fund operating runway and regulatory submissions for Herlystic™.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-19T12:48:48.397842+00:00","company_name":"OS Therapies Inc","ticker":"OSTX","filing_date":"2026-10-19"}]}